H5270
Hydrocortisone 17-butyrate
别名:
11β,17,21-Trihydroxypregn-4-ene-3,20-dione 17-butyrate, Cortisol 17-butyrate
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H36O6
化学文摘社编号:
分子量:
432.55
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.77
表单
solid
质量水平
运输
ambient
储存温度
room temp
SMILES字符串
[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(OC(=O)CCC)C(=O)CO
InChI
1S/C25H36O6/c1-4-5-21(30)31-25(20(29)14-26)11-9-18-17-7-6-15-12-16(27)8-10-23(15,2)22(17)19(28)13-24(18,25)3/h12,17-19,22,26,28H,4-11,13-14H2,1-3H3/t17-,18-,19-,22+,23-,24-,25-/m0/s1
InChI key
BMCQMVFGOVHVNG-TUFAYURCSA-N
基因信息
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
应用
Hydrocortisone 17-butyrate may be used:
- in the synthesis of hydrocortisone butyrate (HB)-loaded poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles
- as a topical corticosteroid (CS) to study its effects on keratinocyte proliferation in hyperproliferant keratinocytes (HaCaT) model
- in the preparation of solid lipid nanoparticles (SLN)
生化/生理作用
Hydrocortisone 17-butyrate is a corticosteroid that acts as a dermocorticoid due to its application in dermatological therapy. It exhibits therapeutic effects against vitiligo of the face and neck.
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
历史批次信息供参考:
Robert Matheson et al.
Journal of drugs in dermatology : JDD, 7(3), 266-271 (2008-04-03)
Hydrocortisone butyrate (HCB) is currently marketed as a cream, ointment, and solution. A new lotion formulation of hydrocortisone butyrate 0.1% (Locoid lotion) has been developed and evaluated. The objective of this study was to evaluate the efficacy and safety of
Hidemi Nakagawa
Clinical drug investigation, 26(5), 235-246 (2006-12-14)
Tacrolimus (FK506) ointment is widely used in the treatment of patients with atopic dermatitis. The drug exerts its action by down-regulating antigen-specific T-cell activities and associated proinflammatory cytokine production. A number of clinical studies have evaluated the efficacy and safety
M Kawashima et al.
The British journal of dermatology, 148(6), 1212-1221 (2003-06-28)
Fexofenadine, a nonsedating, H1-receptor selective antihistamine, exhibits consistent efficacy and safety in the treatment of allergic rhinitis and urticaria. The pruritus associated with atopic dermatitis is considered to be induced, in part, by histamine. Therefore, we thought that fexofenadine may
Lawrence Eichenfield et al.
Pediatric dermatology, 24(1), 81-84 (2007-02-16)
Corticosteroids are currently the first line of treatment for patients with atopic dermatitis. In the pediatric population however, the potential impact of adrenal suppression is always an important safety concern. Twenty boys and girls, 5-12 years of age, with normal
S Reitamo et al.
The British journal of dermatology, 152(6), 1282-1289 (2005-06-14)
Atopic dermatis (AD) is a chronic disease that often requires long-term treatment. Topical corticosteroids are the usual therapy for patients with AD, but prolonged usage can result in skin atrophy and other side-effects. In a randomized, double-blind, comparative study, to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持